+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Oramed Pharmaceuticals Inc (ORMP) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 42 Pages
  • May 2024
  • GlobalData
  • ID: 1322578
Oramed Pharmaceuticals Inc (ORMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Oramed Pharmaceuticals Inc (Oramed) is a pre-clinical pharmaceutical company engaged in the research and development of pharmaceutical solutions. The company is developing products that include an oral insulin capsule for diabetes treatment and orally ingestible capsules for the delivery of other polypeptides. It developed a proprietary platform technology, protein oral delivery (POD) to transform injectable treatments into oral therapies. The technology allows for the oral delivery of drugs and is administered only by injection. Its pipeline products are intended for the treatment of type 1 and type 2 diabetes. The company also focuses on the development of combination therapy of insulin and GLP-1 analogs for the management of type 2 diabetes. Oramed is headquartered in New York City, New York, the US.

Oramed Pharmaceuticals Inc Key Recent Developments

  • Aug 08, 2023: Sorrento Therapeutics Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bid
  • May 01, 2023: Oramed Appoints Ben Shapiro to its Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Oramed Pharmaceuticals Inc - Key Facts
  • Oramed Pharmaceuticals Inc - Key Employees
  • Oramed Pharmaceuticals Inc - Key Employee Biographies
  • Oramed Pharmaceuticals Inc - Major Products and Services
  • Oramed Pharmaceuticals Inc - History
  • Oramed Pharmaceuticals Inc - Company Statement
  • Oramed Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Oramed Pharmaceuticals Inc - Business Description
  • R&D Overview
  • Oramed Pharmaceuticals Inc - Corporate Strategy
  • Oramed Pharmaceuticals Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Oramed Pharmaceuticals Inc - Strengths
  • Oramed Pharmaceuticals Inc - Weaknesses
  • Oramed Pharmaceuticals Inc - Opportunities
  • Oramed Pharmaceuticals Inc - Threats
  • Oramed Pharmaceuticals Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Oramed Pharmaceuticals Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 08, 2023: Sorrento Therapeutics Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bid
  • May 01, 2023: Oramed Appoints Ben Shapiro to its Board of Directors
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Oramed Pharmaceuticals Inc, Key Facts
  • Oramed Pharmaceuticals Inc, Key Employees
  • Oramed Pharmaceuticals Inc, Key Employee Biographies
  • Oramed Pharmaceuticals Inc, Major Products and Services
  • Oramed Pharmaceuticals Inc, History
  • Oramed Pharmaceuticals Inc, Subsidiaries
  • Oramed Pharmaceuticals Inc, Joint Venture
  • Oramed Pharmaceuticals Inc, Key Competitors
  • Oramed Pharmaceuticals Inc, Ratios based on current share price
  • Oramed Pharmaceuticals Inc, Annual Ratios
  • Oramed Pharmaceuticals Inc, Interim Ratios
  • Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Oramed Pharmaceuticals Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Oramed Pharmaceuticals Inc, Performance Chart (2019 - 2023)
  • Oramed Pharmaceuticals Inc, Ratio Charts
  • Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Halozyme Therapeutics Inc
  • CymaBay Therapeutics Inc
  • Ionis Pharmaceuticals Inc
  • Emisphere Technologies Inc
  • Repertoire Immune Medicines Inc
  • Diabetology (Products) Ltd
  • AbbVie Inc
  • Rani Therapeutics LLC
  • MannKind Corp
  • Biodexa Pharmaceuticals PLC
  • Biocon Ltd